[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@3primeAnalytica](/creator/twitter/3primeAnalytica)
"@TohJah7809 😁 green tea for the win matcha's so overpriced in London"  
[X Link](https://x.com/3primeAnalytica/status/1972177642066784677) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-09-28T05:52Z 1272 followers, XX engagements


"Simeon is up $23m on the $CRSP bet he made in July.he's definitely sharing screenshots with his crew now. Too posh for that probably. Might start a tracker website 🙃"  
[X Link](https://x.com/3primeAnalytica/status/1976322679809462537) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-09T16:23Z 1272 followers, XXX engagements


"$REGN's Chris Fenimore (CFO) and Ryan Crowe (SVP IR) participated in a fireside chat at Bernstein yesterday. 📈💊 Stock has declined XX% YTD. I think one of the cheapest underappreciated biopharma LT opptys out there. Comments on $SRRK CRL their own CRL Dupixent Eylea onco pipelline Complement & obesity plays. 📍On EYLEA HD Performance and Headwinds: - Strong sequential demand growth observed: X% in Q1 and XX% in Q2 driven by effective commercial execution and education efforts. - Offering enhanced dosing flex and durability compared to EYLEA 2mg. - Ongoing challenges: securing approvals for"  
[X Link](https://x.com/3primeAnalytica/status/1971230672497820074) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-09-25T15:09Z 1272 followers, 2732 engagements


"🚨 CRISPR News 🧬: AstraZeneca $AZN seals a $555m deal with Algen Biotechnologies for exclusive rights to AI-powered CRISPR therapies targeting immune disorders and cancer - underscoring the tech's accelerating potential to transform DD & spark investor interest. CRISPR's future keeps shining 🚀"  
[X Link](https://x.com/3primeAnalytica/status/1975225660206469311) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-06T15:44Z 1272 followers, 3518 engagements


"$EDIT still a name I won't touch but I know many people are still in it likely just trading it.+184% YTD (went $X in Apr.).still not bad at all for those who traded it this year or who for some reason started investing in it this yr well done I guess. They presented good preclinic in vivo poc data for EDIT-401 last Thursday.mkt didn't care on the 9th definitely not on the 10th either.still progress.still won't touch"  
[X Link](https://x.com/3primeAnalytica/status/1977425295444500974) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-12T17:25Z 1271 followers, 1260 engagements


"FDA slapped Regenxbio with a 3-month delay on RGX-121 for Hunter syndrome - 'more data' is the favourite excuse 🙄. FDA delays continue to pile up = biotech dreams crushed again. $RGNX #FDAFail #Biotech #GeneTherapy 🔥"  
[X Link](https://x.com/3primeAnalytica/status/1958119699918594469) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-08-20T10:51Z 1271 followers, XXX engagements


"$WVE released positive interim results for its RNA-editing therapy WVE-006 primarily developed under a partnership with $GSK which holds the global license and will assume full responsibility post-trial. The data indicate comparable total alpha-1 antitrypsin (AAT) levels to those reported in $BEAM's - XXX program with both achieving approximately 1112 M. However BEAM-302 demonstrates higher relative production of functional M-AAT (91% of total AAT) and a greater reduction in pathogenic Z-AAT (79%) compared to WVE-006 (64% M-AAT and XX% Z-AAT reduction). Waves data does seem to validate"  
[X Link](https://x.com/3primeAnalytica/status/1963235994800365826) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-09-03T13:41Z 1270 followers, 1400 engagements


"@Rainmaker1973 XLOOKUP pretty much replaces VLOOKUP HLOOKUP and INDEX MATCH and it's a lot easier to use"  
[X Link](https://x.com/3primeAnalytica/status/1970439068032082013) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-09-23T10:44Z 1270 followers, XXX engagements


"Here's your Morning CRISPR Brief ☕☀ Recap: $CRBU -XXXX% led losses followed by $NTLA -XXXX% $PRME -XXXX% $EDIT -XXXX% $BEAM -XXXX% $CRSP -XXXX% and $SANA -0.59%. $NTLA announced positive longer-term P1 data for nex-z in patients with ATTR-PN. Data was published in the NEJM showed sustained serum TTR reductions exceeding XX% over three years alongside improvements in neuropathy scores and QoL. Extends the two-year follow-up data presented in May this year reinforced consistency in key parameters. While the results reinforce potential as a SD therapy with deeper suppression than competitors'"  
[X Link](https://x.com/3primeAnalytica/status/1971549578550706421) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-09-26T12:17Z 1272 followers, 2604 engagements


"Here's your Morning CRISPR Brief ☕☀ Recap: smaller caps led gains yet again with $EDIT +8.64% followed by $CRBU +7.98% $SANA +6.00% $BEAM +4.09% $PRME +3.91% $NTLA +3.74% and $CRSP +3.41%. Gains were widespread with volumes moderate but mostly towards the end of the session reflecting cautious trading ahead of key macro data. 📈 Market Pulse: Biotech edged up with $XBI XXX% $IBB X% and $ARKG +1.3%. Combined $CRSP $NTLA and $PRME now account for XX% of $ARKG's allocation (heavy on $CRSP). 💹 Bit of Macro: broad markets edged a little higher with $SPY up XXXX% and $QQQ up XXX% - The 10yr yield"  
[X Link](https://x.com/3primeAnalytica/status/1973009792995135991) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-09-30T12:59Z 1272 followers, 1853 engagements


"Here's your Morning CRISPR Brief ☕☀ Recap: $PRME led gains +19.32% followed by $CRSP +10% $EDIT +9.58% $NTLA +8.96% $SANA +7.30% $BEAM +6% while $CRBU declined -1.33%. - Yesterdays session was absolutely EPIC 🔥 with the rally sustained across these CRISPR names (except CRBU) signalling strong investor confidence in the sector's momentum. - @PrimeMedicine surged back $1bn mc bolstering its positioning after this stellar rebound. This milestone could be key as many institutional funds have minimum mc thresholds that previously restricted participation; now likely to pile in if they see"  
[X Link](https://x.com/3primeAnalytica/status/1974099746332545092) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-03T13:10Z 1270 followers, 2021 engagements


"@_OliverVenture 🔥🔥now superimpose $ARKQ $ARKW $ARKF 😁"  
[X Link](https://x.com/3primeAnalytica/status/1977530046761123889) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-13T00:21Z 1271 followers, XXX engagements


"Here's your Morning CRISPR Brief ☕☀ Recap: gene editing stocks dipped 3-9% on Oct. 10th amid broader market weakness but fundamentals remain intact $CRSP -XXXX% $SANA -XXXX% $NTLA -XXXX% $BEAM -XXXX% $EDIT -XXXX% $PRME -XXXX% $CRBU -9.45%. Big Pharmas interest in CRISPR is heating up again 🔥 as evidenced by several partnerships and deals just last week. The unveiling of a next-gen platform like SyNTase and good poc data reflects steady momentum in the gene editing sector. Some highlights from last week: 1) Non-dilutive win for @BeamTx: $BMY acquired Orbital Therapeutics BEAM's RNA"  
[X Link](https://x.com/3primeAnalytica/status/1977725387820954040) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-13T13:17Z 1271 followers, 2916 engagements